HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David H. Adams Andrew D. Cochrane Asghar Khaghani John D. Smith Magdi H. Yacoub Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, D. H. Articles by Yacoub, M. H. Search for Related Content PubMed PubMed Citation Articles by Adams, D. H. Articles by Yacoub, M. H.

J Thorac Cardiovasc Surg 1994;107:450-0459
© 1994 Mosby, Inc.

Cardiac and Pulmonary Transplantation

Retransplantation in heart-lung recipients with obliterative bronchiolitis

Middlesex, United Kingdom.

From the Cardiothoracic Surgical Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom.

Address for reprints: Professor Magdi Yacoub, Harefield Hospital, Middlesex, UB9 6JH, United Kingdom.

Abstract

Obliterative bronchiolitis remains the leading cause of morbidity and mortality in long-term survivors after heart-lung transplantation. Despite enhanced immunosuppressive therapy, a significant number of patients progress to end-stage respiratory failure, leaving retransplantation as the only potential therapeutic option. Between October 1986 and August 1990, 25 heart-lung recipients (mean age 22 ± 2 years) underwent repeat heart-lung transplantation at an average of 21 months after their first procedure. Twenty-one patients (83%) were ventilator dependent at the time of retransplantation. The Kaplan-Meier survival at 1, 6, 12, and 24 months was 52%, 33%, 25%, and 25%, respectively. Post operative complications included bleeding, multisystem organ failure, and infection. Obliterative bronchiolitis resulted in death or graft failure in three patients between 12 and 36 months after the second transplantation. Five patients were currently alive at the time this article was written, with a median follow-up of 54 months. Three were in New York Heart Association class I, and two had obliterative bronchiolitis with class III symptoms. Recently, we investigated the role of single lung retransplantation in nine heart-lung recipients (mean age 23 ± 3 years). The mean interval between procedures was 36 months, and eight patients (88%) were ventilator dependent. The Kaplan-Meier survival at 1, 6, 12, and 24 months was 89%, 67%, 67%, and 50%, respectively. We observed significantly less perioperative morbidity in this group. Five patients were alive (median follow-up 20 months); four were in New York Heart Association class I or II, and one was in New York Heart Association class III with recurrent obliterative bronchiolitis. We did not have enough patients to perform multivariate survival analysis. Survival curve comparisons with the use of the Wilcoxon test did show that the absence of preformed antibodies in the recipient (panel reactive antibody frequency less than 10%) was associated with significantly improved survival after retransplantation. We also noted trends for improved survival in patients who had retransplantation at least 18 months after their original transplantation and in patients with negative preoperative sputum cultures. Retransplantation is a high-risk procedure that can result in rehabilitation in otherwise incapacitated patients. Single lung retransplantation appears to be the preferred option in carefully selected patients. (J THORAC CARDIOVASC SURG 1994;107:450-9)

This article has been cited by other articles:

				A. Y. Sheikh, M. P. Pelletier, and R. C. Robbins Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1579 - 1608. [Full Text]

				O. Brugiere, G. Thabut, Y. Castier, H. Mal, G. Dauriat, A. Marceau, and G. Leseche Lung Retransplantation for Bronchiolitis Obliterans Syndrome: Long-term Follow-up in a Series of 15 Recipients Chest, June 1, 2003; 123(6): 1832 - 1837. [Abstract] [Full Text] [PDF]

				L. B. Balsam, D. D. Yuh, R. C. Robbins, and B. A. Reitz Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1461 - 1490. [Full Text]

				C. B. Huddleston, E. N. Mendeloff, A. H. Cohen, S. C. Sweet, D. T. Balzer, and G. B. Mallory Jr Lung retransplantation in children Ann. Thorac. Surg., July 1, 1998; 66(1): 199 - 204. [Abstract] [Full Text] [PDF]

				R. J. Novick, L. W. Stitt, K. Al-Kattan, W. Klepetko, H.-J. Schafers, J.-P. Duchatelle, A. Khaghani, R. L. Hardesty, G. A. Patterson, and M. H. Yacoub Pulmonary Retransplantation: Predictors of Graft Function and Survival in 230 Patients Ann. Thorac. Surg., January 1, 1998; 65(1): 227 - 234. [Abstract] [Full Text] [PDF]

				A. Khaghani, F. Santini, C. M. Dyke, O. Onuzu, R. Radley-Smith, and M. H. Yacoub HETEROTOPIC CARDIAC TRANSPLANTATION IN INFANTS AND CHILDREN J. Thorac. Cardiovasc. Surg., June 1, 1997; 113(6): 1042 - 1049. [Abstract] [Full Text]

				R. J. Novick, L. Stitt, H.-J. Schafers, B. Andreassian, J.-P. Duchatelle, W. Klepetko, R. L. Hardesty, A. Frost, and G. A. Patterson PULMONARY RETRANSPLANTATION: DOES THE INDICATION FOR OPERATION INFLUENCE POSTOPERATIVE LUNG FUNCTION? J. Thorac. Cardiovasc. Surg., December 1, 1996; 112(6): 1504 - 1514. [Abstract] [Full Text]

				H. Reichenspurner, R. E. Girgis, R. C. Robbins, J. V. Conte, R. V. Nair, V. Valentine, G. J. Berry, R. E. Morris, J. Theodore, and B. A. Reitz Obliterative Bronchiolitis After Lung and Heart-Lung Transplantation Ann. Thorac. Surg., December 1, 1995; 60(6): 1845 - 1853. [Abstract] [Full Text]

				R. J. Novick, H.-J. Schafers, L. Stitt, B. Andreassian, W. Klepetko, R. L. Hardesty, A. Frost, and G. A. Patterson Seventy-two Pulmonary Retransplantations for Obliterative Bronchiolitis: Predictors of Survival Ann. Thorac. Surg., July 1, 1995; 60(1): 111 - 116. [Abstract] [Full Text]